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ABSTRACT
S-nitrosation is the attachment of a nitric oxide moiety to the thiol side chain of
cysteine. S-nitrosoglutathione (GSNO) acts as a bioactive reservoir for NO to maintain an
equilibrium in the concentration of NO in the body. Due to this, the study of the enzyme
S-nitrosoglutathione reductase has of great interest because of its ability to metabolize
GSNO. S-nitrosoglutathione reductase’s activity has been linked to a number of human
diseases. Chapter 1 of this thesis presents a proposed allosteric binding domain on
GSNOR. Positive cooperativity (sigmoidal deviation) was observed from steady state
analysis of GSNOR which indicated an affinity for the binding of GSNO at this site. The
presence of such a site was further supported by Molecular docking simulations and
HDX-MS which showed that the amino acids Gly321, Lys323, Asn185 and Lys188
interact with molecules bound at this site.
Chapter two introduces four reagents that can function as probes or pseudosubstrates for the monitoring of enzymatic activity as well as measuring concentrations of
free thiols in vitro and live cells. These reagents are N,N-di(thioamido-fluoresceinyl)cystine (DTFCys2), N,N-di(thioamido-fluoresceinyl)-homocystine (DTFHCys2), Namido-O-aminobenzoyl-S-nitrosoglutathione (AOASNOG), and N-thioamidofluoresceinyl-S-nitroso-glutathione (TFSNOG). They are easy to prepare and purity and
can be used in various applications.
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CHAPTER 1
Proposed Allosteric site on S-nitrosoglutathione Reductase

1

Chapter summary
S-nitrosoglutathione reductase, an enzyme in the alcohol dehydrogenase family, is
responsible for the metabolism of GSNO as well as the detoxification of formaldehyde in
the body. Steady state assay of the WT of this enzyme revealed a deviation from the
classical Michaelis Menten kinetics, fitting more into a sigmoidal curve. This led to the
hypothesis that the enzyme has an allosteric site that binds the substrate GSNO and
increases the activity of the enzyme. Molecular docking was used to visualize the
possible location of such a site, and it was found adjacent to the structural zinc. Four
amino acid residues were implicated to have an interaction with the substrate bound at the
site. They are Lys188, Lys323, Asn185 and Gly321. Mutations to the Lysine residues
were performed to monitor how the changes to the environment around this site would
affect the activity of the enzyme and its affinity for binding the substrate. To further
confirm the presence of the proposed allosteric site Hydrogen Deuterium exchange mass
spectroscopy was performed. This exchange showed decreased uptake of deuterium by
three of the four residues at the proposed site identified on the peptide list. Asn185 was
not identified and will be part of the further investigations with respect to this
experiment. All results obtained from the steady state analysis and HDX-MS support the
hypothesis that there is an allosteric site on the enzyme GSNOR located adjacent to the
structural zinc.
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1.1 Nitric Oxide
Nitric Oxide (NO) is a diatomic free radical gasotransmitter. It is the first
identified gasotransmitter discovered to be the endothelium-derived relaxing factor
(EDRF) that is responsible for vascular smooth muscle relaxation. 1-4 NO is a wellestablished signaling molecule involved in many physiological processes. These include
the control of vascular tone and blood pressure, promoting angiogenesis, mediating
neurotransmission, immune response, and wound healing.5 NO is also involved in the
regulation of growth, immunity, environmental and root development of Plants.6
1.1.1 NO Synthases
NO regulation involves the control of nitric oxide synthases (NOS), a group of
enzymes responsible for the biosynthesis of NO. Endogenous NO is enzymatically
synthesized in mammalian tissues by three isoforms of NOS. These isoforms are
neuronal NOS (nNOS, NOS 1), inducible NOS (iNOS, NOS 2) and endothelial NOS
(eNOS, NOS 3) according to basal level of activity and constitutive expression in tissues.
NOSs produce NO in eukaryotic cells which are found in animals, and some algae. Other
organisms utilize alternative methods such as nitrite reduction in the production of NO.7-8
The isoforms of NOS function as homodimers, catalyzing the oxidation of Larginine to L-citrulline and NO in the presence of molecular oxygen with reduced
nicotinamide adenine dinucleotide phosphate (NADPH), as a co-substrate.9-10 NO
productions catalyzed by NOS require a number of cofactors/coenzymes such as flavin
adenine dinucleotide (FAD), flavin mononucleotide (FMN), tetrahydrobiopterin (BH4)
3

and calmodulin. 11 nNOS is natively expressed in the neurons of the peripheral and
central nervous system, in addition to the epithelial cells of various organs.12 nNOS
activity is Ca2+ dependent and NO derived by nNOS mediates synaptic plasticity
affecting complex physiological functions 13-14 and is a part of the central regulation of
blood pressure.15-16 iNOS is expressed in the presence of inducing stimulants like
cytokines. Once induced, it produces substantial amounts of NO and is completely Ca2+
independent. iNOS was discovered in macrophages and is involved in the immune
system and inflammatory bowel disease (IBSs).17-18 eNOS from the name is expressed in
the endothelial cells and just like nNOS is Ca2+ dependent. NO produced by this isoform
results in vasorelaxation and protects blood vessels from thrombosis by the inhibition of
platelet adhesion and aggregation.19-21
1.1.2 NO signaling Mechanism
There are several NO signaling mechanisms that have been identified. The most common
are the classical, nonclassical and less classical mechanisms.22 Classical signaling
involves the activation of soluble guanylate cyclase which then converts guanosine
triphosphate (GTP) to cyclic guanosine monophosphate (cGMP). This leads to the
activation of cGMP-dependent protein kinases subsequently facilitating down-stream
effects. Nonclassical signaling suggests the formation of NO-induced posttranslational
modifications (PTMs) such as S-glutathionylation, S-nitrosation and tyrosine nitration.
The less classical signaling has important implication for cell respiration and intermediate
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metabolism due to the interaction between NO and the mitochondrial cytochrome c
oxidase.23-26

1.2 Protein S-nitrosation
S-nitrosation is the covalent attachment of a nitric oxide (NO) group to the thiol
side chain of the amino acid cysteine resulting in the formation of S-nitrosothiols
(SNOs).27 The post-translational modification of Cysteine residues in proteins has
been regarded as a primary mechanism which NO uses to regulate cell signaling.28-30
S-nitrosation of proteins is not directly catalyzed by enzymes, however protein
catalyzed S-nitrosation and denitrosation pathways have been discovered and are yet
to be understood in the context of global proteomic analysis.29 There has been
increasing evidence that suggests the participation of S-nitrosation in both normal
physiology and pathogenesis of several human diseases.31 For instance, in GSNOR
knockout mice increased levels of SNO-proteins were observed which demonstrates
the role of GSNO/GSNOR in SNO-protein homeostasis. First step in S-nitrosation
process is NO oxidized to higher oxides of nitrogen such as dinitrogen trioxide
(N2O3) when reacted with molecular oxygen (O2). N2O3 can react directly with the
thiols as shown in equation 1.2.1.

RS- + N2O3

RSNO +NO2-

5

Equation 1.2.1

A proposed alternative mechanism for the formation of SNO is the reacting of NO
with reduced thiol forming a radical intermediate.31 Recent evidence shows that the
reaction of NO with molecular oxygen (O2) is not only a primary pathway for Snitrosation of thiols but might also yield products of thiol oxidation sometimes greater
than RSNOs.30,32
S-nitrosation of proteins occurs through transnitrosation. Transnitrosation
reactions are all fully reversible and often include SNOs of low molecular weight
such as GSNO.29,33
Protein-S- + GSNO

Protein-SNO + GS-

Equation 1.2.2

S-nitrosylation is involved in the physiology and dysfunction of cardiac, airway and
skeletal muscle as well as the immune system showing wide-ranging functions in cell
and tissues.34-37
1.3 S-nitrosoglutathione Reductase (GSNOR)
1.3.1 GSNOR as a product of ADH 5
S-nitrosoglutathione Reductase (GSNOR) is an enzyme in the alcohol
dehydrogenase (ADH) family. The alcohol dehydrogenase family has been evolutionarily
conserved from bacteria to man with five distinct classes containing seven known
isoforms.38 ADH is involved in several important roles in the body but the most studied is
the metabolism of short chain alcohols. GSNOR is a member of the class III alcohol

6

dehydrogenase family. GSNOR is encoded by the ADH5 gene located on the reverse
strand of chromosome 4 (4q23-Chr4: 99,993,567-10,000,985).38
GSNOR also known as ADH5, FALDH, GSH-FDH and Formaldehyde
dehydrogenase is a ubiquitously expressed NADH dependent enzyme with the ability to
oxidize medium-chain alcohols and the GSH adduct S-hydroxymethylglutathione
(HMGSH). It also reduces GSNO using NADH as a cofactor producing GSNHOH as an
intermediate which can further react with GSH to produce GSSG and NH2OH. GSNOR
when acting as a glutathione-dependent formaldehyde dehydrogenase is critical in the
metabolic elimination of formaldehyde (Figure 1.3.1). This formaldehyde is eliminated
by reacting with glutathione to produce the adduct S-hydroxymethylglutathione which
can then be oxidized to S-formylglutathione. This reaction requires NAD+ as a cofactor
which leads to the production of NADH, a cofactor necessary for the metabolism of
GSNO.39-41 GSNOR in plants is important for growth and root development. Most of the
studies on GSNOR done on plant are mainly focused on the Arabidopsis thaliana plant
however, there have been papers published on sunflower (Helianthus annuus L.), pepper
(Capsicum annuum L.), maize and rice.42 GSNOR in humans can be found in the
endometrium, ovary, fat, esophagus, prostate, liver and kidney.43

7

Figure 1.3.1: GSNORs role in the detoxification of formaldehyde. In step 1, glutathione reacts with a
formaldehyde at the free thiol group to produce the spontaneous adduct HMGSH. In step 2, HMGSH is
oxidized at the S-hydroxymethyl group by GSNOR to S-formylglutathione using NAD+ as a cofactor.
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1.3.2. GSNOR protein structure
GSNOR functions as a homodimer with 40kDa subunits containing 347 amino
acids per subunit (Figure 1.3.2, page 11). In each subunit there is a catalytic domain and a
coenzyme binding domain. GSNOR is a metalloprotein with two zinc atoms per
monomer for a total of four zinc atoms per functional enzyme. The zinc atoms are both in
the catalytic domain however the catalytic zinc acts as a lewis acid during catalysis while
the structural zinc is critical for the maintenance of proper protein structure. GSNOR
requires a coenzyme that may vary depending on the substrate. These include NADH,
NADPH+H+ and, NAD(P)+.44
The amino acid residues involved in the binding of substrates are highly
conserved, particularly Glu68 and Arg379 as they are integral to the catalysis
mechanism.45,46 The catalytic zinc is coordinated by the residues Cys45, His67, Cys174
and Glu68 or a water molecule. Similarly, the structural zinc is coordinated by four
closely spaced cysteine residues Cys97, Cys100, Cys103 and Cys111.47,48 Although the
structural zinc is not involved in the catalytic mechanism mutations to any of the cysteine
residues results in the enzymes inactivity. The catalytic domain moves towards the
coenzyme binding domain during the formation of the complex HMGSH with NADH
present.
We hypothesize the presence of an allosteric site on GSNOR that binds the
substrate GSNO and enhances the activity of the enzyme. This site is postulated to be
localized in a cleft adjacent to the structural zinc atom. Four amino acid residues in this
9

local with molecules bound at this site. The amino acid residues involved are Lys323,
Gly321, Asn185 and Lys188 with both Lysine residues proposed to interact indirectly
with molecules while the Glycine and Asparagine residues interact directly with bound
molecules. This was Supported by molecular docking (MD) simulations performed on the
enzyme and the substrate GSNO.

10

Figure 1.3.2 GSNOR crystal structure showing the 40kDa subunits. (A) the enzyme structure showing the
four zinc atoms. The active site is located in the cleft between the catalytic zinc and the structural zinc. (B)
shows the catalytic zinc coordinated by two of the three Cysteine residues and the Histidine. (C) shows the
structural zinc coordinated by the four Cysteine residue in close proximity of each other were two of the
residues make up the CXXC motif of the Enzyme.
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1.3.3. Functions of GSNOR
GSNOR as previously mentioned is highly conserved in eukaryotic and
prokaryotic organisms and expressed in all tissues studied.49,50 Multiple studies have
provided documentation of the involvement of GSNOR in a number of pathways from
metabolism of GSNO,51-55 to w-hydroxy fatty acid oxidation,56,57 and formaldehyde
detoxification.58-61 The most characterized and studied functions of GSNOR are the
glutathione-dependent formaldehyde oxidation and the NADH-dependent GSNO
reduction (fig 1.3.1 and fig 1.3.3). The glutathione-dependent formaldehyde
dehydrogenase activity is important for the elimination of formaldehyde, a classified
carcinogen because of its high reactivity with DNA and proteins.62 Studies have shown
that GSNOR is localized in the cytoplasm and as a condensed chromatin in the nucleus,63
this supports its function in the elimination of formaldehyde and protecting DNA from its
toxicity.
The substrates that are preferred by GSNOR are HMGSH and GSNO. However,
GSNO is considered the best substrate due to its catalytic efficiency of metabolism being
twice that of HMGSH.64 GSNO is metabolized by the reductase activity of GSNOR with
the first step being the reduction of GSNO in the presence of the NADH to the unstable
intermediate glutathione N-hydroxysulfenamide (GSNHOH). In the presence of excess
GSH in the system, GSNHOH will react with the GSH to produce a glutathione dimer
(GSSG) and a side product of Hydroxylamine (NH2OH) (Figure 1.3.3). When no GSH is
present the reaction can go in a different direction with GSNHOH spontaneously forming
12

glutathione sulfonamide (GSNONH2) which can then be hydrolyzed under acidic
conditions to glutathione sulfonic acid (GSOOH) and ammonia (NH4+). The above
reaction schemes are all irreversible.
Under physiological conditions, the ratio of NADH/NAD+ present is typically
low.65 This is not favorable for reductive pathways that require NADH implying that the
reductase activity of GSNOR may depend on the availability of the cofactor. An increase
in cellular NADH levels can be triggered by various factors like the inhibition of NADH
dehydrogenase.66 GSNOR deficient mice exhibit substantial increases in protein snitrosation.67 In the cellular environment GSNO is observed to be in equilibrium with Snitrosated proteins via reversible transnitrosation, while the observation of increased
levels of S-nitrosation places GSNOR in a crucial role for the maintenance of SNO
homeostasis by reducing GSNO.

13

Figure 1.3.3 Reaction scheme showing how GSNOR works. (A) shows the process by which the substrate
GSNO is metabolized by the enzyme GSNOR in the presence of the cofactor NADH to the unstable
intermediate GSNHOH. (B) GSNHOH in the presence of excess GSH will react further to produce GSSG.
(C) When there is no GSH present GSNHOH spontaneous produces GSONH2 which can be further
hydrolyzed to produce Glutathione sulfuric acid and Ammonia

14

1.3.4. Physiology and Inhibitors of GSNOR
GSNOR plays a crucial role in the variation of NO in the cells. NO is highly
reactive and will form stable RSNO equilibrium in the presence of GSH in the form of
GSNO, a reservoir of bioavailable NO. NO and by extension GSNO plays a critical role
in the relaxation of smooth muscle,68-70 cardiopulmonary regulation71-73, and several other
intra/extracellular functions.74 GSNOR dysregulation has been implicated in numerous
diseases such as asthma, cystic fibrosis and intestinal lung disease. GSNOR knockout
mice have been used to obtain valuable data related to GSNOR function. Canonical NOmediated pathways and RSNO levels are severely modified when GSNOR activity is
modulated. GSNOR plays an important protective role in the immune system’s
development of lymphocytes. GSNOR knockout mice show a decrease in CD4
thymocyte development and an increase in lymphocytic apoptosis.75 GSNOR’s regulation
activity in the brain affects a broad swath of cellular functions ranging from neural
development to other neurodegenerative diseases seen in adults.
GSNO has been identified as a long-lived and potent relaxant of human airway
in pulmonary physiology, due to its role as a reservoir for NO. This is characterized by
inflammation and hyper-responsiveness in the airway.76 GSNO has been linked to other
diseases like IBS, autoimmune encephalomyelitis and more. An increase in SNO levels in
knockout mice with asthma lead to the study of therapeutic approaches for the inhibition
of GSNOR activity to restore SNO levels. Investigations into inhibitors of GSNOR are
on-going to aid patients affected by some of the diseases. The most productive progress
15

in the regulation of GSNOR is the development of N9115, an inhibitor marketed as
Cavosonstat, that assists cystic fibrosis (CF) patients with the DF508-CFTR mutation.
This mutation occurs within the gene for the cystic fibrosis transmembrane conductance
regulator (CFTR) and accounts for most of cases of CF.77,78 N91115 ensures the
availability of GSNO to promote CFTR development and plasma membrane stability via
its inhibition of GSNOR.
1.4 Computational study of the proposed allosteric site
A computational study of the enzyme to identify the location of the proposed
allosteric site via the measurement of minimum energy between the substrate and the
enzyme was conducted using molecular docking simulations. This study was done as a
collaboration between Sahar Nikoo, Dr. James Gauld, Dr. Bei Sun, and Dr. Bulent
Mutus. The crystal structure for GSNOR utilized was obtained from the PDB library
(ID:3QJ5) and was loaded onto the Molecular Environment Software (MOE). This study
revealed that at the speculated site, the bound ligand interacts with four amino acid
residues. These are lysine188, lysine323, glycine321 and asparagine185 (Figure 1.4). The
docking results showed that when GSNO is bound at the proposed site, it interacts
directly with the residues Gly321 and Asn185. The results also show that Lys188 and
Lys323 interact with GSNO via a solvent network of hydrogen bonds.5 Docking scores
obtained from this study show a score of -8.60 when GSNO is bound to the known active
site of the enzyme and a score of -10.4 when GSNO binds to the postulated allosteric site.
Docking scores are used to predict the binding affinity of a molecule with a low score
16

showing the system is stable and shows the interaction is favorable. This study further
confirms the presence of the proposed allosteric binding site for the substrate GSNO.

Figure 1.4 Molecular docking simulation showing the location of the proposed allosteric site and how
when GSNO is bound it interacts with the implicated residues direct or via the solvent network of hydrogen
bonds. The interactions via hydrogen bonds are shown by the blue lines.
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1.5 Hydrogen deuterium exchange (HDX) MS
A Hydrogen deuterium exchange experiment was carried out using a Synapt G1
that was properly fitted with custom TRESI apparatus as per Wilson et al.53 The reagents
used for this are reported in appendix B from the work done by Kathleen Fontana. The
experiment was performed using 5- and 10-mm reaction spaces corresponding to 2 and 4
seconds, respectively. Data collection was done in IMS mode within the range of 4001500 m/z. Experimental uptake of deuterium for each peptide was calculated using a
software that was custom-built for this purpose. Data was collected on the same day for
all trials. These include 5-minute spectrums of GSNOR without deuterium exchange,
with two- and four-seconds exchanges. This was followed by 5 min spectrums of
GSNOR + 20x GSNO (excess) with the same conditions as mentioned above.
1.5.1 (HDX) MS Results
The results from the HDX experiments seen in Appendix B supports the presence
of the proposed allosteric binding site. The incorporation of deuterium shows a shift in
the distribution of peaks due to the addition of the heavier isotope. This shift
corresponded to the amount of deuterium being acquired by the peptide. 20x GSNO was
used to ensure the availability of the substrate in the reaction to enable easy observation
of the interaction with the active site and the proposed allosteric site. Three of the four
amino acid residues that were implicated to be involved in the interaction at the proposed
site by computational studies are represented by the identified peptide list (appendix B).
They are Lys188, Lys323 and Gly321.The results from the two- and four- seconds
18

experiment showed that most of the peptides had an increase in the uptake of deuterium
and is summarized in Table 1.5.1. All other relevant results are in appendix B.

Table 1.5.1 Change in Deuterium uptake by the residues implicated in allosteric binding.

The Gly321, Lys188 and Lys323 residues that are associated with the allosteric site
were identified by peptide MS-MS. These residues as well as those that surround the
GSNO molecule from the computational study all showed a decrease in the uptake of
deuterium. Lys323 showed the highest rate of decrease at 1.4%, Lys188 a decrease of
0.4% and Gly321 which was represented twice on the peptide list showed decreases of
0.9% and 1.4%. Peptides leading to the active site pocket as well as those involved in the
binding of NADH and the catalytic zinc also showed a decrease in the uptake of
deuterium. The 2 second exchange provided changes in peptide within the ranges of -
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1.8% to + 3.4% and -5.2% to +5.1% for deuterium uptake, respectively. These results
support the presence of the allosteric site on the enzyme GSNOR as proposed.
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1.6 Method and Materials
1.6.1 GSNOR WT cloning and Protein isolation
The ADH5 cDNA used for this project was initially cloned by Dr. Bei Sun, who also
performed mutagenesis on said gene that resulted in the recombinant GSNOR with 6xhistidine tags at each terminus as outline in appendix A. The pET28b_ADH5 was then
transformed into BL21(DE3) E.coli cells to facilitate purification of the enzyme.
Protein purification begins with a single colony from the transformed BL21 cells
grown on LB Kanamycin agar plates. The colony is grown in a sterile polypropylene
culture tube containing 4ml of 2x YT media with 50 µg/ml of Kanamycin. The culture
tubes are left to grow overnight at 37ºC while shaking for further use in growing a starter
culture at a rate of 1ml of colony per 100ml of media under the same conditions. The
starter culture is used to inoculate 1.5L of 2x YT media containing 50 µg/ml of
Kanamycin and grown at 37 ºC until an optical density of 0.5-0.6 is reached. At this
point, GSNOR expression is induced by the addition of IPTG to a final concentration of
0.4mM. The induced culture was left for 24 hours at room temperature with shaking to
incubate. The cells were then collected by centrifugation at 6000rpm, 4ºC for 30 minutes.
The supernatant was discarded, and the pellet resuspended with lysis buffer, composed of
50mM Tris-HCl, 150mM NaCl, 15mM imidazole, 1mM DTT, 1mM PMSF, 1% Triton
X-100, 75µg/ml DNase I and 100µg/ml Lysozyme at pH8. The lysate was incubated on
ice for 30mins and further lysed by pulse sonification (20 seconds on and 20 seconds off
for a total of 8 pulses). Another round of centrifugation at 12000rpm,4ºC for 30mins was
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performed and the supernatant further purified using a HIS-select Nickel Affinity Gel
from Sigma-Aldrich (P6611).
The Nickel column was equilibrated with a wash buffer (with no imidazole) and
Affinity purification was performed by following the manufacturer’s protocol published
by Sigma with modifications to buffer compositions. The wash buffer was composed of
50mM Tris-HCl, 150mM NaCl and 40mM imidazole, while the elution buffer was
composed of 50mM Tris-HCl, 150mM NaCl and 300mM imidazole both at pH 8. The
eluted protein was then buffer exchanged into a storage solution at pH 7.4, composed of
58mM Na2HPO4, 17mM of na2H2PO4, 68mM NaCl and 15% glycerol, using Amicon
centrifugal 30,000 NMWL filter (Millipore sigma UFC 903008) and stored at -80ºC.

1.6.2 GSNO synthesis
Reduced glutathione was dissolved in a solution of cold water and 2 M HCl. An
equal amount of sodium nitrite was added, and the reaction mixture was stirred at 4ºC in
the dark for 40 minutes. GSNO was then precipitated using 10 mL of cold acetone and
the final pink product was washed with cold water and cold acetone before it was
lyophilized for storage at -20ºC. All steps followed as per Hart’s method.80 The final
product was verified by obtaining absorbance readings at 335 nm.
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1.6.3 GSNOR Kinetics
Steady state analysis was performed on GSNOR WT and three mutants by varying
GSNO as the substrate while keeping enzyme and NADH constant. A stock solution of
20mM NADH was prepared using milli-Q water. GSNO stock solutions of 1mM and
10mM were freshly prepared for each experiment using PBS buffer. GSNO of increasing
concentration was added to a cuvette containing 80µM of NADH and PBS to a final
reaction volume of 500µl. The reaction was initiated by the addition of 2µg of enzyme.
The consumption of NADH during the reaction was monitored using the decrease in
absorbance at 340nm over a period of 60 seconds using the Agilent 8453 UV/Vis
spectrophotometer. The rate of the initial linear decrease corresponding to NADH uptake
was plotted in correlation to the concentration of GSNO. From this, KM, Vmax and
Catalytic efficiency kcat were calculated.
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1.7 Results
Steady state analysis of GSNOR WT revealed a sigmoidal deviation [Figure 1.7.1
(i)] resulting in positive cooperativity. This led to the proposal of a possible allosteric site
on the enzyme. Molecular docking simulations were performed to further investigate the
presence of the allosteric binding site for the substrate GSNO. Hydrogen-Deuterium
exchange experiments were also performed by Kathleen Fontana to investigate direct
ligand interactions as per appendix B.

1.7.1 GSNOR Kinetics
Steady state kinetic assays of the WT were performed with the concentrations of
NADH and enzyme kept constant while the concentration of GSNO was varied from
0uM to 700uM. Upon analysis of experimental data obtained, the apparent KM, and Vmax
were calculated and are summarized in Table 1.5.1. The Hill coefficient was used to
quantitatively determine the cooperativity of ligand binding. The Hill constant observed
was 1.61 ± 0.14. Mutations at the proposed allosteric binding site were used to observe
changes in the rate of ligand binding and how important the Lysine residues are for
binding. Lysine (K) residues at position 188 and 323 were mutated to alanine (A). Three
mutants were studied; a double mutant and single mutants at each position. For each
mutant KM, Vmax were determined. Hill constant (n) obtained from the data set are
summarized in table 1.5.1. From the Hill constant obtained, it was inferred that the
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enzyme was displayed positive cooperativity for the WT while the mutant K188A loses
the sigmoidal activity. Negative cooperativity can be seen for the mutants K323A and
K188/323A. This shows that both WT and K188A have an affinity for the ligand to bind
at this site however once the mutation at the other position as well as the double mutation
occurs all ligand binding affinity was lost.

Table 1.7.1: Summary of experimental data obtained for the KM, Vmax, Hill constant, Kcat and the
catalytic efficiency of GSNOR WT and three mutants
WT

K188A

K323A

K188/323A

KM (µM)

22.01 ± 3.8

28.51 ± 4.7

N/D

N/D

Vmax (µM/s)

0.0058 ± 0.0003

0.0052 ± 0.0003

0.0012 ± 0.0003

0.0019 ± 0.0001

Hill constant (n)

1.61 ± 0.14

0.9 ± 0.085

0.1 ± 0.014

0.34 ± 0.21

Kcat (s-1)

58,000

52,000

12,000

19,000

Kcat/KM (s-1µM-1)

2,624

1,824

N/D

N/D

25

Figure 1.7.1 (i) Plots of the kinetic data obtained for GSNOR WT and GSNOR K188A. The left panel shows
the full Michaelis Menten plots (blue line) as well as the sigmoidal curve (red line) however the deviation
cannot be seen. The right panel shows a zoom in plot at the lower concentrations, this shows the deviations
from the classical Michaelis Menten plot.
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Figure 1.7.1.ii Plots of the kinetic data obtained for GSNOR K323A and GSNOR K188/323A. The left
panel shows the full Michaelis Menten plots (blue line) as well as the sigmoidal curve (red line) however
the deviation cannot be seen. The right panel shows a zoom in plot at the lower concentrations, this shows
the deviations from the classical Michaelis Menten plot.
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1.8 Discussion
The data obtained from the computational, steady state kinetics and HDX-MS studies
of GSNOR support the hypothesis that there is indeed an allosteric site for the binding of
the substrate GSNO present on the enzyme GSNOR.
The steady state assay first performed on GSNOR WT showed a slight deviation
from the Michalis Menten plot when a Hill constant was applied to fit a sigmoidal curve
which led to the hypothesis of the presence of the proposed allosteric site and the desire
to study it. In an attempt to understand how the presence of an allosteric site affects
enzyme function, mutational study was done.
The steady state assay performed gave results that show difference in KM, Vmax, and
Hill constant. As table 1.5.1 shows the WT and mutant K188A show KM values that are
close to the literature value of 27µM81 while the KM values of K323A and K188/323A
decreases drastically. This shows that the mutations occurring at these sites lead to an
almost complete loss in affinity for substrate binding that could be because of
conformational changes in the enzyme structure. This was further confirmed by the Hill
constant which showed positive cooperativity for the WT, non-cooperativity for the
mutant K188A and negative cooperativity for the other mutants. The graphs show a slow
rate moving towards the KM but a much faster rate on its way to the Vmax. The steady
state data shows that although the computational study suggests that Lys323 does not
interact directly with the substrate, the almost complete loss of activity after mutation
suggests otherwise.
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These results show that the activity of GSNOR is hyper-sensitive to structural
changes at this other-than the active site. This is favorable for pharmaceutical companies
that have been investigating the inhibition of this enzyme for treating diseases affiliated
with the enzyme. This discovery could aid the company in designing small molecules that
can attack the lysine residue at position 323 for instance.
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1.9 Conclusion
The results obtained from (1) the steady state assay with a Hill constant of 1.61±0.14
for GSNOR WT and decreasing Hill constant for the mutants; (2) the results from the
HDX-MS which showed a decrease in deuterium uptake of 1.4%, 0.4%, 0.9% and 1.4%
for Lys323, Lys188, and (3) the two Gly321 peptides identified from the reaction of
GSNOR and excess GSNO reaction; support the hypothesis that the enzyme GSNOR has
an allosteric site present that binds the substrate GSNO, increases its rate of reaction, and
is more fitted to the sigmoidal curve plot than the classical Michalis Menten. This site
could be a potential target for pharmaceutical company in developing molecules that can
disrupt GSNOR’s activity by attacking there.
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1.10 Future direction
To confirm the location and presence of an allosteric site, several steps may be taken
in future experiments. First the mutation of the Lysine residue to another residue similar
in size and charge to determine if the loss of the charge or the bulk side chain plays a role
in the loss of affinity for the substrate. In addition, more HDX-MS trials should be
performed to provide further confirmation.
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CHAPTER 2
Development of fluorogenic pseudo-substrates
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Chapter Summary
This chapter describes the theoretical basis and the methods employed in
synthesizing and characterizing four fluorogenic probes/pseudo substrates. The four
probes synthesized are N,N-di(thioamido-fluoresceinyl)-cystine (DTFCys2), N,Ndi(thioamido-fluoresceinyl)-homocystine (DTFHCys2), N-amido-O-aminobenzoyl-Snitrosoglutathione (AOASNOG), and N-thioamido-fluoresceinyl-S-nitroso-glutathione
(TFSNOG). These probes can be used in measuring and imaging free thiols present on
cell surfaces, as substrates for the thiol reductase and S-nitrosothiol denitrosylase
activities of the protein disulfide isomerase (PDI). It can also be used as a substrate for
the S-nitrosothiol reductase activity of GSNOR in vitro and on live cells.
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2.1 Fluorescence: A brief introduction
Fluorescence is a luminescence process involving susceptible molecules that emit
light from electronically excited states made by either a physical or chemical mechanism.
Fluorescence occurs by the absorption of photons in a singlet ground state to a singlet
excited state. As the excited molecule returns to the ground state, it emits a photon of
lower energy that corresponds to a longer wavelength than the absorbed photon. The
energy loss is due to vibrational relaxation while in the excited state. Fluorescent bands
center at wavelengths longer this shift towards the longer wavelengths is known as the
stokes shift.82 Excited states are short-lived with a lifetime at about 10-8 seconds.
Substance luminescence is affected by the molecular structure and the chemical
environment. The molecular structure and chemical environment also determine the
intensity of emission when luminescence does occur. In general molecules that can
fluoresce are conjugated systems and the specific frequencies of excitation and emission
are dependent on the molecule or atom.
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Figure 2.1 Jablonski diagram of absorbance, non-radiative decay and fluorescence.
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2.2 Fluorescein
The fluorescein dye is the most commonly used fluorescent probe due to its high
molar absorptivity at a wavelength 494nm, making it a very useful and sensitive
fluorescent label. Fluorescein is commercially available in many derivatives, the major
one been Fluorescein isothiocyanate. Fluorescein isothiocyanate (FITC) is simply the
original fluorescein molecule that was functionalized with an isothiocyanate reactive
group which replace a hydrogen atom on the bottom ring of the structure. FITC is often
used in cellular biology to label and track cells in fluorescence microscopy applications.
FITC reacts readily with nucleophiles such as the amine and sulfhydryl groups of
proteins. Many moieties can be conjugated with FITC making them useful in a wide
variety of experimental procedures from immunofluorescence, Apoptosis detection,
Nucleotide labelling, to in situ hybridization and many more.83

Figure 2.2 A shows the fluorescein molecule, B shows the dianion form of fluorescein which give the best
intensity of fluorescence and C shows the functionalized fluorescein molecule, the Fluorescein
isothiocyanate derivative
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2.3 The redox probes
The highlighted reagents would theoretically act as probes and pseudo substrates
for several reactions. Three of such reactions are the enzyme catalyzed disulfide
reduction (Equation 2.3.1), S-nitrosothiol denitrosylation by the release of NO or HNO
(Equation 2.3.2) and the reduction of NO+ to NH2OH (Equation 2.3.3).
R-S-S-R

2 RSH

Equation 2.3.1

R-S-N=O

NO + ½ RS-SR

Equation 2.3.2

R-S-N=O

NH2OH + ½ RS-SR

Equation 2.3.3

The four probes are fluorogenic, therefore when they partake in thiol redox
reactions an increase in their fluorescence can be observed. The probes are N,Ndi(thioamido-fluoresceinyl)-cystine (DTFCys2, figure 2.3A), N,N-di(thioamidofluoresceinyl)-homocystine (DTFHCys2, figure 2.3B), N-amido-O-aminobenzoyl-Snitrosoglutathione (AOASNOG, figure 2.3D), and N-thioamido-fluoresceinyl-S-nitrosoglutathione (TFSNOG, figure 2.3C). Intra-molecular quenching in these probes account
for their low fluorescence when they are not a part of a reaction. Quenching in DTFCys2
is due to the proximity of the two fluorophores to each as a result of structural stability
via intramolecular H-bonding. The self-quenching is results from the collisional energy
transfer that leads to thermalization of the electronic excitation energy. Fluorescence
quenching in AOASNOG and TFSNOG occurs due to the overlap in spectrum of the
functional group, S-N=O (lmax = 312nm and 545nm) with either the excitation (lmax =
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494nm) or emission (lmax = 520nm) spectrum of fluorescein because of the close
proximity of the functional group to the fluorophore.

Figure 2.3 MM2 energy minimized and 2D structures of A- DTFCys2, B- DTFHCys2, C-TFSNOG and DAOASNOG. The black lines indicate intramolecular H-bonds
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2.4 Materials
Glutathione (reduced), Isatoic anhydride, fluorescein isothiocyanate (FITC),
Cystine, Homocystine, and sephadex G-50 were all purchased from Sigma Aldrich. Silica
plateTM TLC plates were purchased from SiliCycle Inc.
2.5 Methods
2.5.1 N,N-di(thioamido-fluoresceinyl)-cystine (DTFCys2, figure 2.3.1A)
L-Cystine (0.1mmol) was dissolved in 3.0mL of 0.1M sodium carbonate solution.
This was added to a solution of 0.25mmol FITC dissolved in 3.0mL of acetone. This was
left to react for 24 hours at 50°C protected from light. The reaction mixture was
lyophilized and applied onto a 2.5cm x 30cm Econo column filled with Sephadex G-50
that has been equilibrated with water. DTFCys2 was eluted using 3 column volumes and
the fraction was concentrated by lyophilization, dissolved in water and divided into
100mL aliquots for freezing at -20°C. The final product was characterized using NMR,
UV/Vis, and Fluorescence spectroscopy. The 1H-NMR spectrum was characterized by
the fluoresceinyl-protons ranging from 5.7 to 7.4ppm, and multiplets corresponding to the
Cys protons all summarized in Table C1 of appendix C. The UV/Vis spectrum was
characterized by the large fluoresceinyl-absorbance peak (lmax = 494nm, eM=176,000 M1

cm-1). There was also a shoulder due to the fluoresceinyl-moieties overlapping at 475nm.

The absorbance contributions of the S-N=O moiety was buried within the broad aromatic
contribution from the fluorescein moiety.
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2.5.2 N,N-di(thioamido-fluoresceinyl)-homocystine (DTFHCys2, figure 2.3.2B)
The procedure for the synthesis of DTFHCys2 was the same as that used for
DTFCys2 with 0.1mmol L-Homocystine. The final product was characterized using
NMR, UV/Vis, and Fluorescence spectroscopy. The 1H-NMR spectrum was like that of
DTCys2 with the addition of two peaks all summarized in Table C1 of appendix C. The
UV/Vis spectrum was characterized by the large fluoresceinyl-absorbance peak (lmax =
494nm, eM=176,000 M-1cm-1). There was also a shoulder due to the fluoresceinylmoieties overlapping at 475nm that was seen for DTFCys2.

2.5.3 N-amido-O-aminobenzoyl-S-nitrosoglutathione (AOASNOG, figure 2.3.2D)

S-nitrosoglutathione was synthesized using Hart’s Method.80 SNOG (0.32mmol)
and 1.84mmol Isatoic anhydride (recrystallized from isopropanol) which were dissolved
in 0.5M phosphate buffer pH8 and left to react for 24 hours at 22°C protected from light.
The reaction mixture was applied to a 1cm x 10cm Econo column packed with 1g of
QAE-Sephadex equilibrated with water. The column was washed with 50mL of water
and the AOASNOG was eluted using 0.1M phosphate buffer containing 0.5M NaCl pH
7.4. The product was concentrated by lyophilization, dissolved in 2.0mL of water and
divided into aliquots for freezing at -20°C. AOASNOG was characterized using NMR,
UV/Vis, and Fluorescence spectroscopy. The 1H-NMR spectra of SNOG and
AOASNOG were compared. The largest chemical shift change observed in the
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AOASNOG spectrum which indicated the presence of the o-aminobenzoyl group and
aromatic protons. The NMR results are summarized in Table C2 of appendix C.84 The
UV/Vis spectrum is characterized by a broad peak that consist of the absorbance of
o-aminobenzoyl (lmax = 312 nm, eM= 2,800 M-1cm-1) and a shoulder from the -SNO
group (lmax = 335 nm, eM= 920 M-1cm-1). There was also a small contribution in the red
range (lmax = 545 nm, eM=16 M-1cm-1) due to the second weaker -SNO absorbance.85
The fluorescence properties of AOASNOG have previously been detailed, further
confirming that AOASNOG is weakly fluorescent because of the close spatial and
overlapping spectra of the excitation spectrum of o-aminobenzoyl-moiety and the
-S-N=O absorbance. This shows that AOASNOG has the ability to act as a fluorogenic
reporter of chemical changes to the -S-N=O functionality through the loss of NO+ or the
reduction of -S-N=O to -S-NHOH by enzymes like S-nitrosoglutathione reductase
(GSNOR) leading to a 14 fold increase in fluorescence at 412nm.84

2.5.4 N-thioamido-fluoresceinyl-S-nitroso-glutathione (TFSNOG, figure 2.3.2C)

S-nitrosoglutathione (0.3mmol) was dissolved in 4mL of 0.2M NaHCO3 pH 9. This
solution was then added to a solution of 0.1mmol FITC dissolved in 4mL of acetone.
This was left to react for 4 hours at 22°C protected from light. The product was applied to
a 1.5cm x 10cm Econo column packed with 2mL of Dowex-1 (Cl- form). FITC and GSH
do not have a strong interaction with the Dowex-1 because at pH 7 they have net charges
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of -2 and -1, respectively. However, TFSNOG at pH 7 has a net charge of -4 and has a
strong interaction with the Dowex-1. Isolation of the product was started by washing the
with 50mL of 0.1M Tris-HCl pH 7.4 and the TFSNOG eluted using the same buffer
containing 1M NaCl. The eluate was concentrated by lyophilization then re-dissolved in
0.5mL of water and desalted on a packed column of 15mL Sephadex G-25 equilibrated
using distilled water. The fraction containing TFSNOG was collected, concentrated by
lyophilization, and divided into aliquots for freezing at -20°C.
TFSNOG was characterized using NMR, UV/Vis, and Fluorescence spectroscopy.
The 1H-NMR spectra of TFSNOG showed a range of 6.3ppm to 7.6ppm for the aromatic
protons of the fluoresceinyl-moiety and peaks for multiplets corresponding to the proton
of Glu and Gly of SNOG all summarized in Table C1 of appendix C. UV/Vis spectrum of
TFSNOG showed a large absorbance peak for the fluoresceinyl-moiety (lmax = 494 nm,

eM=88,000 M-1cm-1) with the contribution from the -SNO moiety buried within the broad
peak. TFSNOG has a low fluorescence because of the overlap between the -S-N=O
absorbance, lmax = 545nm and the fluoresceinyl-emission, lmax = 520 nm. The
fluorescence increases upon denitrosylation with DTT.
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2.6 Results

Figure 2.6 A: UV/Vis spectrum of DTFCys2 (red dash line), DTFHCys2 (blue dash line) and
TFSNOG (black dash line); B: Fluorescence emission spectrum of TFSNOG before (dash
line) and after the addition of DTT (50µM, red line); C: Fluorescence emission spectrum of
DTFCys2 before (red dash) and after the addition of DTT (50µM, red line). Fluorescence
emission spectrum of DTFHCys2 before (blue dash) and after the addition of DTT (50µM,
blue line).
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2.6.1 Free thiol determination
DTFCys2 and DTFHCys2 can be used as fluorescent reagents for detecting free thiol
concentration just like Ellman’s reagent86 via the thiol disulfide exchange shown in
Equation 2.6.1. This reagent can be used to determine nmol levels of free thiols (Figure
2.6.1).
F-Cys-S-S-Cys-F + RS- ® R-S-S-Cys-F + F-Cys-Slow fluorescence

Equation 2.6.1

higher fluorescence

Figure 2.6.1 Constant volume of DTFCys2 (A) and DTFHCys2 (B) were added to
the first 9 wells of a 96-well plate. The first two well were used as control and to
wells 4-6 increasing amounts of DTT (blue) were added. Wells 7-9 had increasing
amounts of GSH (red). Each point accounts for the increase in thiol concentration.
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2.6.2 Kinetic Characterization of disulfide reductases in vitro and in live cells
Researchers had shown that cells have a cell surface associated form of PDI.87-97
DTFCys2 can also be used to kinetically characterize pure recombinant PDI and cell
surface PDI of ARPE cells. These reagents can also be used in imaging cell surface thiols
from PDI to other free protein thiols on live cells. Figure 2.6.2b shows ARPE cells
exposed to DTFCys2.

Figure 2.6.2a; A: constant volume of purified recombinant PDI was added to 96-well plates
with increasing amounts of DTFCys2 and enzymatic reaction was initiated by the addition of
DTT. B: ARPE cells grown to confluence in wells of a 96-well plate had increasing amounts
of DTFCys2 added to it the wells and change in fluorescence was monitored at 520nm for 9
minutes. The fit used to estimate the value of KM is showed as the red dashed line.
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Figure 2.6.2b ARPE cells grown at the bottom of 96-well plates exposed to PBS (control)- panel A, B, C
and DTFCys2- Panel D, E, F for 15 mins. imaged from the bottom of the plate using an inverted
epifluorescence microscope (Zeiss Axiovert 200) equipped with an FITC cube. Overlay of the DIC images
of the cells done with the aid of Corel paint shop pro 2018.
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2.6.3 Kinetic characterization of S-nitrosoglutathione reductase in vitro and live cells

AOASNOG is currently the only cell permeable, pseudo-substrate for Snitrosoglutathione reductase.84 This section demonstrates how it can be used to
kinetically characterize ARPE cells (Figure 2.6.3B). TFSNOG the fluorescein analog of
AOASNOG acts as a pseudo-substrate for the S-denitrosylation activity of PDI.98

Figure 2.6.3 A: constant volume of purified PDI with increasing amounts of TFSNOG were added to the
wells of a 96-well plate and enzymatic activity was initiated by the addition of DTT. B: ARPE cells grown
to confluence in wells of a clear 96-well plate had increasing amounts of AOASNOG added to the wells.
Changes in fluorescence was monitored at 520nm (A) and 412 (B) every 35s for 9 minutes.
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2.7 Discussion
The purpose of this study was to describe the theoretical basis and simple methods
for synthesizing four probes/reagents that can be used in various applications such as the
measuring and imaging of free thiols on cell surface as well as how they can perform as
pseudo-substrates for monitoring enzymatic activities. Each reagent was characterized
using NMR as well as UV/Vis and Fluorescence spectroscopy. Thin Layer
Chromatography (TLC) was performed using SiliaPlate TLC aluminum backed plates
with varying mobile phases that provided the best separation. The mobile phase used for
DTFCys2, DTFHCys2, and TFSNOG was acetone:water:methanol in a 10:10:1 ratio. For
AOASNOG the mobile phase composition was acetone:water:methanol in a 13:6:1 ratio.
The multiple spots observed for FITC are due to the different prototrophic forms of
fluorescein.107
The disulfide-linked probes DTFCys2 and DTFHCys2 can function as fluorescent
reagents for the detection of free thiol concentrations just like the classical colorimetric
thiol reagent 5,5’-dithiobis-2-nitrobenzoate (Ellman’s reagent) from the thiol disulfide
exchange. However, unlike the Ellman’s reagent, the fluorescence signal from these new
regents enables the detection of thiol concentrations in the nmol levels. DTFCys2 can be
used to kinetically characterize recombinant PDI and cell surface PDI of ARPE in culture
with estimated KM for the PDI mediated disulfide reduction which was ~1.9µM and was
close to the estimated KM for the ARPE-surface PDI of 2.72µM. the Michaelis Menten
equation was used to estimate the steady-state kinetic parameters from a fit of the data. A
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KM of 740µM was estimated for AOASNOG in the ARPE-GSNOR catalyzed
denitrosation which comes close to the KM for recombinant GSNOR of 320µM. TFSNOG
functions as a pseudo-substrate for the S-denitrosylase activity of PDI with an estimated
KM of 11.1µM that corresponds to a higher affinity of about 6-fold compared to that of
SNOG (65µM). Unfortunately, TFSNOG was not a pseudo-substrate for GSNOR. Apart
from the large applications to enzymology and cell biology, the reagents cost less to
produce because the fluorescein isothiocyanate is less expensive than eosin
isothiocyanate for example. In addition, fluorescein derivatives are much easier to purify.

2.8 Conclusion
The reagents outlined here are easy to prepare and purify. They can be used in
diverse applications ranging from their use as thiol reagents to pseudo-substrates for
monitoring enzymatic activities in vitro.

49

REFERENCES/BIBLIOGRAPHY

1.

Furchgott, R. F.; Zawadski, J. Acetylcholine Relaxes Arterial Smooth-Muscle by
Releasing a Relaxing Substance from Endothelial-Cells. Fed Proc 39:581-581; 1980.

2.

Ignarro, L. J.; Buga, G. M.; Wood, K. S.; Byrns, R. E.; Chaudhuri, G. EndotheliumDerived Relaxing Factor Produced and Released from Artery and Vein Is NitricOxide. P Natl Acad Sci USA 84:9265-9269; 1987.

3.

Palmer, R. M. J.; Ferrige, A. G.; Moncada, S. Nitric-Oxide Release Accounts for the
Biological-Activity of Endothelium-Derived Relaxing Factor. Nature 327:524-526;
1987.

4.

Furchgott, R. F.; Khan, M. T.; Jothianandan, D. Comparison of EndotheliumDependent Relaxation and Nitric Oxide-Induced Relaxation in Rabbit Aorta. Fed
Proc 46:385-385; 1987.

5.

Sun, B. Biochemical and Functional Studies of S-nitrosoglutathione Reductase and
Neutral Sphingomyelinase II. University of Windsor, Electronic Theses and
Dissertations, 2017

6.

Moncada, S.; Radomski, M. W.; Palmer, R. M. J. Endothelium-Derived Relaxing
Factor - Identification as Nitric-Oxide and Role in the Control of Vascular Tone and
Platelet-Function. Biochem Pharmacol 37:2495-2501; 1988.

7.

Ignarro, L. J.; Byrns, R. E.; Burga, G. M.; Wood, K. S., Endothelium-Derived
Relaxing Factor From Pulmonary Artery and Vein Possesses Pharmacologic and
50

Chemical Properties Identical to Those of Nitric Oxide Radical. Circulation Research
1987, 61 (6), 866-879.
8.

Ignarro, L. J.; Burga, G. M.; Wood, K. S.; Byrns, R. E.; Chaudhuri, G., Endotheliumderived relaxing factor produced and released from artery and vein is nitric oxide.
Proc Natl Acad Sci U S A 1987, 84 (24), 9265-9269

9.

Stuehr, D. J.; Kwon, N. S.; Nathan, C. F.; Griffith, O. W.; Feldman, P. L.; Wiseman,
J. N omega-hydroxy-L-arginine is an intermediate in the biosynthesis of nitric oxide
from L-arginine. J Biol Chem 266:6259-6263; 1991.

10. Knowles, R. G.; Moncada, S. Nitric-Oxide Synthases in Mammals. Biochem J
298:249-258; 1994.
11. Forstermann, U.; Closs, E. I.; Pollock, J. S.; Nakane, M.; Schwarz, P.; Gath, I.;
Kleinert, H. Nitric-Oxide Synthase Isozymes - Characterization, Purification,
Molecular- Cloning, and Functions. Hypertension 23:1121-1131; 1994.
12. Forstermann, U.; Sessa, W. C. Nitric oxide synthases: regulation and function.
Eur Heart J 33:829-+; 2012.
13. Bohme, G. A.; Bon, C.; Lemaire, M.; Reibaud, M.; Piot, O.; Stutzmann, J. M.;
Doble, A.; Blanchard, J. C. Altered Synaptic Plasticity and Memory Formation in
Nitric- Oxide Synthase Inhibitor-Treated Rats. P Natl Acad Sci USA 90:9191-9194;
1993.
14. Zhou, L.; Zhu, D. Y. Neuronal nitric oxide synthase: Structure, subcellular
localization, regulation, and clinical implications. Nitric Oxide-Biol Ch 20:223-230;
51

2009.
15. Togashi, H.; Sakuma, I.; Yoshioka, M.; Kobayashi, T.; Yasuda, H.; Kitabatake, A.;
Saito, H.; Gross, S. S.; Levi, R. A Central-Nervous-System Action of Nitric-Oxide in
Blood-Pressure Regulation. J Pharmacol Exp Ther 262:343-347; 1992.
16. Esplugues, J. V. NO as a signalling molecule in the nervous system. Brit J
Pharmacol 135:1079-1095; 2002.
17. Kolios, G.; Valatas, V.; Ward, S. G., Nitric oxide in inflammatory bowel disease: a
universal messenger in an unsolved puzzle. Immunology 2004, 113 (4), 427-437.
18. Nathan, C. F.; Hibbs, J. B. Role of Nitric-Oxide Synthesis in Macrophage
Antimicrobial Activity. Current Opinion in Immunology 3:65-70; 1991.
19. Fleming, I.; Busse, R. Molecular mechanisms involved in the regulation of the
endothelial nitric oxide synthase. Am J Physiol-Reg I 284:R1-R12; 2003.
20. Azuma, H.; Ishikawa, M.; Sekizaki, S. Endothelium-Dependent Inhibition of
Platelet-Aggregation. Brit J Pharmacol 88:411-415; 1986.
21. Li, H. G.; Forstermann, U. Nitric oxide in the pathogenesis of vascular disease.
Journal of Pathology 190:244-254; 2000.
22. Martínez-Ruiz, A., Cadenas, S., & Lamas, S. (2011). Nitric oxide signaling:
Classical, less classical, and nonclassical mechanisms. Free Radical Biology And
Medicine, 51(1), 17-29. doi: 10.1016/j.freeradbiomed.2011.04.010
23. Brown, G. C.; Cooper, C. E. Nanomolar Concentrations of Nitric-Oxide Reversibly
Inhibit Synaptosomal Respiration by Competing with Oxygen at Cytochrome52

Oxidase. Febs Lett 356:295-298; 1994.
24. Martinez-Ruiz, A.; Cadenas, S.; Lamas, S. Nitric oxide signaling: Classical, less
classical, and nonclassical mechanisms. Free Radical Bio Med 51:17-29; 2011.
25. Erusalimsky, J. D.; Moncada, S. Nitric oxide and mitochondrial signaling from
physiology to pathophysiology. Arterioscl Throm Vas 27:2524-2531; 2007.
26. Hess, D., Matsumoto, A., Kim, S., Marshall, H., & Stamler, J. (2005). Protein Snitrosylation: purview and parameters. Nature Reviews Molecular Cell Biology, 6(2),
150-166. doi: 10.1038/nrm1569
27. Forman, H. J.; Fukuto, J. M.; Torres, M. Redox signaling: thiol chemistry defines
which reactive oxygen and nitrogen species can act as second messengers. Am J
Physiol- Cell Ph 287:C246-C256; 2004.
28. Foster, M. W.; Hess, D. T.; Stamler, J. S. Protein S-nitrosylation in health and
disease: a current perspective. Trends Mol Med 15:391-404; 2009.
29. Hickok JR, Vasudevan D, Thatcher GRJ, and Thomas DD. Is S-nitrosocysteine a
true surrogate for nitric oxide? Antioxid Redox Signal 17: 962–968, 2012.
30. Thomas, D. D. and D. Jourd'heuil (2012). "S-Nitrosation: Current Concepts and New
Developments." Antioxidants & Redox Signaling 17(7): 934-936.
31. Gow, A. J.; Buerk, D. G.; Ischiropoulos, H. A novel reaction mechanism for the
formation of S-nitrosothiol in vivo. J Biol Chem 272:2841-2845; 1997.
32. Benhar, M.; Forrester, M. T.; Stamler, J. S. Protein denitrosylation: enzymatic
mechanisms and cellular functions. Nat Rev Mol Cell Bio 10:721-732; 2009.
53

33. Benhar, M., Forrester, M., Hess, D., & Stamler, J. (2008). Regulated Protein
Denitrosylation by Cytosolic and Mitochondrial Thioredoxins. Science, 320(5879),
1050-1054. doi: 10.1126/science.1158265
34. Palmer, L., Kavoussi, P., & Lysiak, J. (2012). S-Nitrosylation of endothelial nitric
oxide synthase alters erectile function. Nitric Oxide, 27, S22-S23. doi:
10.1016/j.niox.2012.04.079
35. He, W., & Frost, M. (2016). Direct measurement of actual levels of nitric oxide (NO)
in cell culture conditions using soluble NO donors. Redox Biology, 9, 1-14. doi:
10.1016/j.redox.2016.05.002
36. Beuve, A., Wu, C., Cui, C., Liu, T., Jain, M., & Huang, C. et al. (2016).
Identification of novel S-nitrosation sites in soluble guanylyl cyclase, the nitric oxide
receptor. Journal Of Proteomics, 138, 40-47. doi: 10.1016/j.jprot.2016.02.009
37. Guerra, D., Ballard, K., Truebridge, I., & Vierling, E. (2016). S-Nitrosation of
Conserved Cysteines Modulates Activity and Stability of S-Nitrosoglutathione
Reductase (GSNOR). Biochemistry, 55(17), 2452-2464. doi:
10.1021/acs.biochem.5b01373
38. Jensen, D. E.; Belka, G. K.; Bois, G. C. D., S-Nitrosoglutathione is a substrate for rat
alcohol dehydrogenase class III isoenzyme. Biochem J 1998, 331, 659-668.
39. Hedberg, J. J.; Hoog, J.-O.; Nilsson, J. A.; Xi, Z.; Elfwing, Å.; Grafstro, R. C.,
Expression of alcohol dehydrogenase 3 in tissue and cultured cells from human oral
mucosa. Am J Pathol 2000, 157 (5), 1745-1755.
54

40. Hopkinson, R. J.; Barlow, P. S.; Schofield, C. J.; Claridge, T. D. W., Studies on the
reaction of glutathione and formaldehyde using NMR. Org Biomol Chem 2010, 8
(24), 4915-4920.
41. Leterrier, M.; Chaki, M.; Airaki, M.; Valderrama, R.; Palma, J. M.; Barroso, J. B.;
Corpas, F. J., Function of S-nitrosoglutathione reductase (GSNOR) in plant
development and under biotic/abiotic stress. Pant Signal Behav 2011, 6 (6), 789-793.
42. Fagerberg, L.; Hallstro, B. M.; Oksvold, P.; Kampf, C.; Djureinovic, D.; Odeberg, J.;
Habuka, M.; Tahmasebpoor, S.; Danielsson, A.; Edlund, K.; Asplund, A.; Sjostedt,
E.; Lundberg, E.; Szigyarto, C. A.-K.; Skogs, M.; Takanen, J. O.; Berling, H.; Tegel,
H.; Mulder, J.; Nilsson, P.; Schwenk, J. M.; Lindskog, C.; Danielsson, F.;
Mardinoglu, A.; Sivertsson, Å.; Feilitzen, K. v.; Forsberg, M.; Zwahlen, M.; Olsson,
I.; Navani, S.; Huss, M.; Nielsen, J.; Ponten, F.; Uhlen, M., Analysis of the Human
Tissue-specific Expression by Genome-wide Integration of Transcriptomics and
Antibody-based Proteomics. Molecular & Cellular Proteomics 2014, 13 (2), 397406.
43. Yang, Z. N.; Bosron, W. F.; Hurley, T. D. Structure of human chi chi alcohol
dehydrogenase: A glutathione-dependent formaldehyde dehydrogenase. J Mol Biol
265:330-343; 1997.
44. Barnett, S. D.; Buxton, I. L. O., The Role of S-nitrosoglutathione Reductase
(GSNOR) in Human Disease and Therapy. Crit Rev Biochem Mol Biol 2017, 52 (3),
340- 354.
55

45. Sanghani, P. C.; Davis, W. I.; Zhai, L.; Robinson, H., Structure-Function
Relationships in Human Glutathione-Dependent Formaldehyde Dehydrogenase. Role
of Glu-67 and Arg-368 in the Catalytic Mechanism. Biochemistry 2006, 45, 48194830.
46. Kubienová, L.; Kopecný, D.; Tylichová, M.; Briozzo, P.; Skopalová, J.; Sebela, M.;
Navrátil, M.; Tâche, R.; Luhová, L.; Barroso, J. B.; Petrivalský, M., Structural and
functional characterization of a plant S-nitrosoglutathione reductase from Solanum
lycopersicum. Biochimie 2013, 95 (4), 889-902.
47. Auld, D. S.; Bergman, T. The role of zinc for alcohol dehydrogenase structure and
function. Cell Mol Life Sci 65:3961-3970; 2008.
48. Jelokova, J.; Karlsson, C.; Estonius, M.; Jornvall, H.; Hoog, J. O. Features of
Structural Zinc in Mammalian Alcohol-Dehydrogenase - Site-Directed Mutagenesis
of the Zinc Ligands. Eur J Biochem 225:1015-1019; 1994.
49. Adinolfi, A.; Adinolfi, M.; Hopkinson, D. A. Immunological and BiochemicalCharacterization of the Human Alcohol-Dehydrogenase Chi-Adh Isozyme. Annals of
Human Genetics 48:1-10; 1984.
50. Estonius, M.; Svensson, S.; Hoog, J. O. Alcohol dehydrogenase in human tissues:
Localisation of transcripts coding for five classes of the enzyme. Febs Lett 397:338342; 1996.
51. Jensen, D. E.; Belka, G. K.; Du Bois, G. C. S-Nitrosoglutathione is a substrate for rat
alcohol dehydrogenase class III isoenzyme. Biochem J 331 ( Pt 2):659-668; 1998.
56

52. Thompson, C. M.; Ceder, R.; Grafstrom, R. C. Formaldehyde dehydrogenase:
Beyond phase I metabolism. Toxicol Lett 193:1-3; 2010.
53. Staab, C. A.; Hellgren, M.; Hoog, J. O. Dual functions of alcohol dehydrogenase 3:
implications with focus on formaldehyde dehydrogenase and S-nitrosoglutathione
reductase activities. Cell Mol Life Sci 65:3950-3960; 2008.
54. Godoy, L.; Gonzalez-Duarte, R.; Albalat, R. S-nitrosogluthathione reductase activity
of amphioxus ADH3: insights into the nitric oxide metabolism. Int J Biol Sci 2:117124; 2006.
55. Kubienova, L.; Ticha, T.; Jahnova, J.; Luhova, L.; Petrivalsky, M. SNitrosoglutathione Reductase: The Key Enzyme Regulator of S-nitrosylation. Chem
Listy 107:202-208; 2013.
56. Jensen, D. E.; Belka, G. K.; Du Bois, G. C. S-Nitrosoglutathione is a substrate for rat
alcohol dehydrogenase class III isoenzyme. Biochem J 331 ( Pt 2):659-668; 1998.
57. Koivusalo, M.; Baumann, M.; Uotila, L. Evidence for the identity of glutathionedependent formaldehyde dehydrogenase and class III alcohol dehydrogenase. Febs
Lett 257:105-109; 1989.
58. Jones, D. P.; Thor, H.; Andersson, B.; Orrenius, S. Detoxification Reactions in
Isolated Hepatocytes - Role of Glutathione Peroxidase, Catalase, and Formaldehyde
Dehydrogenase in Reactions Relating to N-Demethylation by Cytochrome-P-450
System. J Biol Chem 253:6031-6037; 1978.
59. Sanghani, P. C.; Stone, C. L.; Ray, B. D.; Pindel, E. V.; Hurley, T. D.; Bosron, W.F.
57

Kinetic mechanism of human glutathione-dependent formaldehyde dehydrogenase.
Biochemistry-Us 39:10720-10729; 2000.
60. Hedberg, J. J.; Hoog, J. O.; Nilsson, J. A.; Xi, Z.; Elfwing, A.; Grafstrom, R. C.
Expression of alcohol dehydrogenase 3 in tissue and cultured cells from human oral
mucosa. Am J Pathol 157:1745-1755; 2000.
61. Teng, S.; Beard, K.; Pourahmad, J.; Moridani, M.; Easson, E.; Poon, R.; O'Brien, P.
J. The formaldehyde metabolic detoxification enzyme systems and molecular
cytotoxic mechanism in isolated rat hepatocytes. Chem-Biol Interact 130:285-296;
2001.
62. Thrasher, J. D.; Kilburn, K. H. Embryo toxicity and teratogenicity of formaldehyde.
Arch Environ Health 56:300-311; 2001.
63. Iborra, F. J.; Renaupiqueras, J.; Portoles, M.; Boleda, M. D.; Guerri, C.; Pares, X.
Immunocytochemical

and

Biochemical

Demonstration

of

Formaldehyde

Dehydrogenase (Class-Iii Alcohol-Dehydrogenase) in the Nucleus. J Histochem
Cytochem 40:1865- 1878; 1992.
64. Hedberg, J. J.; Griffiths, W. J.; Nilsson, S. J. F.; Höög, J.-O., Reduction of Snitrosoglutathione by human alcohol dehydrogenase 3 is an irreversible reaction as
analysed by electrospray mass spectrometry. Eur J Biochem 2003, 270 (6), 12492156.
65. Williamson, D. H.; Lund, P.; Krebs, H. A. Redox State of Free NicotinamideAdenine Dinucleotide in Cytoplasm and Mitochondria of Rat Liver. Biochem J
58

103:514-+; 1967.
66. Staab, C. A.; Hellgren, M.; Hoog, J. O. Dual functions of alcohol dehydrogenase 3:
implications with focus on formaldehyde dehydrogenase and S-nitrosoglutathione
reductase activities. Cell Mol Life Sci 65:3950-3960; 2008.
67. Liu, L.; Yan, Y.; Zeng, M.; Zhang, J.; Hanes, M. A.; Ahearn, G.; McMahon, T. J.;
Dickfeld, T.; Marshall, H. E.; Que, L. G.; Stamler, J. S. Essential roles of Snitrosothiols in vascular homeostasis and endotoxic shock. Cell 116:617-628; 2004.
68. Barnett, S. D. and I. L. O. Buxton (2017). "The role of S-nitrosoglutathione reductase
(GSNOR) in human disease and therapy." Crit Rev Biochem Mol Biol 52(3): 340354.
69. Que, L. G., et al. (2009). "S-nitrosoglutathione reductase: an important regulator in
human asthma." Am J Respir Crit Care Med 180(3): 226-231.
70. Spadaro, D., et al. (2010). "The redox switch: dynamic regulation of protein function
by cysteine modifications." Physiol Plant 138(4): 360-371.
71. Staab, C. A., et al. (2008). "Reduction of S-nitrosoglutathione by alcohol
dehydrogenase 3 is facilitated by substrate alcohols via direct cofactor recycling and
leads to GSH-controlled formation of glutathione transferase inhibitors." Biochem J
413(3): 493-504.
72. Hess, D. T. and J. S. Stamler (2012). "Regulation by S-nitrosylation of protein posttranslational modification." J Biol Chem 287(7): 4411-4418.
73. Fernandez, M. R., et al. (2003). "S-nitrosoglutathione reductase activity of human
59

and yeast glutathione-dependent formaldehyde dehydrogenase and its nuclear and
cytoplasmic localisation." Cell Mol Life Sci 60(5): 1013-1018.
74. Miersch, S. and B. Mutus (2005). "Protein S-nitrosation: biochemistry and
characterization of protein thiol-NO interactions as cellular signals." Clin Biochem
38(9): 777-791.
75. Jahnova, J., et al. (2019). "S-Nitrosoglutathione Reductase-The Master Regulator of
Protein S-Nitrosation in Plant NO Signaling." Plants (Basel) 8(2).
76. Cohn, L.; Elias, J. A.; Chupp, G. L. ASTHMA: Mechanisms of disease persistence
and progression. Annu Rev Immunol 22:789-815; 2004.
77. Bobadilla, J. L.; Macek, M. J.; Fine, J. P.; Farrell, P. M., Cystic fibrosis: A
worldwide analysis of CFTR mutations—correlation with incidence data and
application to screening. Hum Mutat 2002, 19 (6), 575-606.
78. Green, L. S.; Chun, L. E.; Patton, A. K.; Sun, X.; Rosenthal, G. J.; Richards, J. P.,
Mechanism of Inhibition for N6022, a First-in-Class Drug Targeting SNitrosoglutathione Reductase. Biochemistry 2012, 51, 2157-2168.
79. Fontana, K. Studies on Nitric Oxide Generation and its Enzymatic Degradation.
Electronic Theses and Dissertations, 2018
80. Hart, T. W. (1985) Some Observations Concerning the S-Nitroso and SPhenylsulfonyl Derivatives of L-Cysteine and Glutathione. Tetrahedron Lett 26,
2013-2016
81. Jensen, D. E.; Belka, G. K.; Du Bois, G. C. S-Nitrosoglutathione is a substrate for
60

rat alcohol dehydrogenase class III isoenzyme. Biochem J 331 ( Pt 2):659-668; 1998.
82. Geddes, C., Parfenov, A., Roll, D., Uddin, M., & Lakowicz, J. (2003). Fluorescence
Spectral Properties of Indocyanine Green on a Roughened Platinum Electrode:
Metal-Enhanced Fluorescence. Journal Of Fluorescence, 13(6), 453-457. doi:
10.1023/b:jofl.0000008055.22336.0b
83. Sjöback, R., Nygren, J., & Kubista, M. (1995). Absorption and fluorescence
properties of fluorescein. Spectrochimica Acta Part A: Molecular And Biomolecular
Spectroscopy, 51(6), L7-L21. doi: 10.1016/0584-8539(95)01421-p
84. Johnson, M. (2011). FITC/Fluorescein. Materials And Methods, 1. doi:
10.13070/mm.en.1.189

85. Sun, B. L., Palmer, L., Alam, S. R., Adekoya, I., Brown-Steinke, K., Periasamy, A.,
and Mutus, B. (2017) O-Aminobenzoyl-S-nitrosoglutathione: A fluorogenic, cell
permeable, pseudo-substrate for S-nitrosoglutathione reductase. Free Radic Biol Med
108, 445-451
86. Hart, T. W. (1985) Some Observations Concerning the S-Nitroso and SPhenylsulfonyl Derivatives of L-Cysteine and Glutathione. Tetrahedron Lett 26,
2013-2016
87. Ellman, G. L. (1958) A colorimetric method for determining low concentrations of
mercaptans. Arch Biochem Biophys 74, 443-450
88. Raturi, A., Miersch, S., Hudson, J. W., and Mutus, B. (2008) Platelet microparticle61

associated protein disulfide isomerase promotes platelet aggregation and inactivates
insulin. Biochim Biophys Acta 1778, 2790-2796
89. Root, P., Sliskovic, I., and Mutus, B. (2004) Platelet cell-surface protein disulphideisomerase mediated S-nitrosoglutathione consumption. Biochem J 382, 575-580
90. Liu, H., Chen, J., Li, W., Rose, M. E., Shinde, S. N., Balasubramani, M., Uechi, G.
T., Mutus, B., Graham, S. H., and Hickey, R. W. (2015) Protein disulfide isomerase
as a novel target for cyclopentenone prostaglandins: implications for hypoxic
ischemic injury. FEBS J 282, 2045-2059
91. Zai, A., Rudd, M. A., Scribner, A. W., and Loscalzo, J. (1999) Cell-surface protein
disulfide isomerase catalyzes transnitrosation and regulates intracellular transfer of
nitric oxide. J Clin Invest 103, 393-399
92. Pan, S., Chen, H. H., Correia, C., Dai, H., Witt, T. A., Kleppe, L. S., Burnett, J. C.,
Jr., and Simari, R. D. (2014) Cell surface protein disulfide isomerase regulates
natriuretic peptide generation of cyclic guanosine monophosphate. PLoS One 9,
e112986
93. Kallakunta, V. M., Slama-Schwok, A., and Mutus, B. (2013) Protein disulfide
isomerase may facilitate the efflux of nitrite derived S-nitrosothiols from red blood
cells. Redox Biol 1, 373-380
94. Prado, G. N., Romero, J. R., and Rivera, A. (2013) Endothelin-1 receptor antagonists
regulate cell surface-associated protein disulfide isomerase in sickle cell disease.
FASEB J 27, 4619-4629
62

95. Wan, S. W., Lin, C. F., Lu, Y. T., Lei, H. Y., Anderson, R., and Lin, Y. S. (2012)
Endothelial cell surface expression of protein disulfide isomerase activates beta1 and
beta3 integrins and facilitates dengue virus infection. J Cell Biochem 113, 1681-1691
96. Vallon, M., Aubele, P., Janssen, K. P., and Essler, M. (2012) Thrombin-induced
shedding of tumour endothelial marker 5 and exposure of its RGD motif are
regulated by cell-surface protein disulfide-isomerase. Biochem J 441, 937-944
97. Bi, S., Hong, P. W., Lee, B., and Baum, L. G. (2011) Galectin-9 binding to cell
surface protein disulfide isomerase regulates the redox environment to enhance Tcell migration and HIV entry. Proc Natl Acad Sci U S A 108, 10650-10655
98. Zhang, L. M., St Croix, C., Cao, R., Wasserloos, K., Watkins, S. C., Stevens, T., Li,
S., Tyurin, V., Kagan, V. E., and Pitt, B. R. (2006) Cell-surface protein disulfide
isomerase is required for transnitrosation of metallothionein by S-nitroso-albumin in
intact rat pulmonary vascular endothelial cells. Exp Biol Med (Maywood) 231, 15071515
99. Sliskovic, I., Raturi, A., and Mutus, B. (2005) Characterization of the S-denitrosation
activity of protein disulfide isomerase. J Biol Chem 280, 8733-8741
100.Akhter, S., Green, J. R., Root, P., Thatcher, G. J., and Mutus, B. (2003) Peroxynitrite
and NO+ donors form colored nitrite adducts with sinapinic acid: potential
applications. Nitric Oxide 8, 214-221
101.Chen, X., Wen, Z., Xian, M., Wang, K., Ramachandran, N., Tang, X., Schlegel, H.
B., Mutus, B., and Wang, P. G. (2001) Fluorophore-labeled S-nitrosothiols. J Org
63

Chem 66, 6064-6073
102.Ramachandran, N., Jacob, S., Zielinski, B., Curatola, G., Mazzanti, L., and Mutus, B.
(1999) N-dansyl-S-nitrosohomocysteine a fluorescent probe for intracellular thiols
and S-nitrosothiols. Biochim Biophys Acta 1430, 149-154
103.Ramachandran, N., Root, P., Jiang, X. M., Hogg, P. J., and Mutus, B. (2001)
Mechanism of transfer of NO from extracellular S-nitrosothiols into the cytosol by
cell-surface protein disulfide isomerase. Proc Natl Acad Sci U S A 98, 9539-9544
104.Nikitovic, D., and Holmgren, A. (1996) S-nitrosoglutathione is cleaved by the
thioredoxin system with liberation of glutathione and redox regulating nitric oxide. J
Biol Chem 271, 19180-19185
105.Jensen, D. E., Belka, G. K., and Du Bois, G. C. (1998) S-Nitrosoglutathione is a
substrate for rat alcohol dehydrogenase class III isoenzyme. Biochem J 331 ( Pt 2),
659-668
106.Liu, L., Hausladen, A., Zeng, M., Que, L., Heitman, J., and Stamler, J. S. (2001) A
metabolic enzyme for S-nitrosothiol conserved from bacteria to humans. Nature 410,
490-494
107.Liu, L., Hausladen, A., Zeng, M., Que, L., Heitman, J., Stamler, J. S., and
Steverding, D. (2001) Nitrosative stress: protection by glutathione-dependent
formaldehyde dehydrogenase. Redox Rep 6, 209-210
108.Bateman, R. L., Rauh, D., Tavshanjian, B., and Shokat, K. M. (2008) Human
carbonyl reductase 1 is an S-nitrosoglutathione reductase. J Biol Chem 283, 3575664

35762
109.Klonis, N., and Sawyer, W. H. (1996) Spectral properties of the prototropic forms of
fluorescein in aqueous solution. J Fluoresc 6, 147-157
110.Raturi, A., and Mutus, B. (2007) Characterization of redox state and reductase
activity of protein disulfide isomerase under different redox environments using a
sensitive fluorescent assay. Free Radic Biol Med 43, 62-70
111.Caba, C., Ali Khan, H., Auld, J., Ushioda, R., Araki, K., Nagata, K., and Mutus, B.
(2018) Conserved Residues Lys(57) and Lys(401) of Protein Disulfide Isomerase
Maintain an Active Site Conformation for Optimal Activity: Implications for PostTranslational Regulation. Front Mol Biosci 5, 18
112.Onukwue, N., Ventimiglia, L., Potter, M., Aljoudi, S. and Mutus, B. (2019). Simple
fluorescent reagents for monitoring disulfide reductase and S-nitroso reductase
activities in vitro and in live cells in culture. Methods.

65

APPENDICES

APPENDIX A – Recombinant GSNOR
Figure A.1: Recombinant wild type GSNOR protein sequence.
Figure A.2: Recombinant GSNOR Plasmid Map.
APPENDIX B – Mass Spectrometry to identify peptides of GSNOR
Figure B.1: GSNOR peptide Map
Table B.1: Full peptide list resulting from MS-MS identification.
Table B.2: Representative peptide to visualize deuterium uptake
Table B.3: Deuterium uptake results of two seconds reaction time
Table B.4: Deuterium uptake results of four seconds reaction time
Figure B1: HDX-MS heat map after two seconds of deuterium exchange
Figure B2: HDX-MS heat map after four seconds of deuterium exchange
Figure B3 (i-iv): HDX-MS heat maps with dimerized GSNOR

APPENDIX C – Supplementary Data for the development of fluorogenic pseudosubstrates.
Table C1: 1H-NMR chemical shifts for the outlined reagents
Table C2: 1H-NMR chemical shift for GSNO and AOASNOG (OAbz-GSNO)
Figure C1: TLC of starting materials and the products

66

APPENDIX A – Recombinant GSNOR

Figure A.1: Recombinant wild type GSNOR protein
sequence. Amino acids are numbered from Met1 to Ile374,
excluding the added histidine-tag (italicized).
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Figure A.2: Recombinant GSNOR Plasmid Map.

The following was designed and performed by Dr Bei Sun.5 Human ADH5 was
purchased from Origene (SC119755) and sub-cloned into the bacterial expression
vector pET28b using Cold Fusion Cloning Kit (MJS BioLynx Inc. SYMC010A1).
The following primers for PCR were designed according to manufacturer’s
guidelines:
Forward 5’ –GTGCCGCGCGGCAGCCATATGGCGAACGAGGTTATCAAG– 3’
Reverse 5’ –GTGGTGGTGGTGGTGCTCGAGAATCTTTACAACAGTTCGAATG– 3’

Colonies were screened using diagnostic restriction enzyme digest and by
partial sequencing (Robarts Research Institute, London Regional Genomics
Center, London, Ontario, Canada). The final recombinant GSNOR contains a 6Xhistidine tag at each terminus.
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APPENDIX B – Mass Spectrometry to identify peptides of GSNOR 79
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150

160
170
180
VVADISVAKI
DPLAPLDKVC
LLGCGISTGY

KFCLNPKTNL
MGTSTFSEYT

190
200
210
220
GAAVNTAKLE
PGSVCAVFGL
GGVGLAVIMG
CKVAGASRII
230

240
250
260
RAKEFGATEC
INPQDFSKPI
QEVLIEMTDG

270

280
290
300
NVKVMRAALE ACHKGWGVSV VVGVAASGEE

310

320
330
340
GRTWKGTAFG
GWKSVESVPK
LVSEYMSKKI

GVDINKDKFA
GVDYSFECIG
IATRPFQLVT
250
KVDEFVTHNL

360
SFDEINKAFE

370
374
VVKI
LMHSGKSIRT

LEHHHHHH
Figure B.1 GSNOR Peptide Map
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Table B.1: Full peptide list resulting from MS-MS identification. Theoretical amino
acid number corresponds to labels beginning at Met1, whereas experimental amino acid
numbers include the His tags of the recombinant protein. 292 total amino acids have been
sequenced, however only 188 unique amino acids have coverage, resulting in a 52%
sequence coverage of the 374 relevant residues. 48% coverage with His tags included.
m/
z

Theoretical
Amino Acid
Number

Experimental
Amino Acid
Number

Amino Acid Sequence

813.3543
690.0621
621.4647
545.9043
406.9651
457.5103
508.7969
462.4796
762.2355
749.1952
1260.826
1017.545
889.3751
863.8682
796.6921
903.3278
646.5185
1091.721
1074.582
537.7998
950.457
1053.654
669.6493
726.2026
818.1564
1061.054
1038.94
1173.876
587.3912
1241.154
965.4494
1231.957

0-6
7-11
11-22
25-43
35-41
35-42
42-56
52-56
64-79
66-81
75-87
78-87
91-98
131-138
139-145
187-195
190-203
194-205
210-220
211-221
223-230
228-236
231-242
233-246
239-245
246-254
315-324
320-330
324-334
334-343
353-360
354-363

20-26
27-33
31-42
45-54
55-61
55-62
62-76
72-76
84-99
86-101
95-107
98-107
111-118
151-158
159-165
207-215
210-223
214-225
230-240
231-241
243-250
248-256
251-262
253-265
259-265
266-274
335-344
340-350
344-354
354-363
373-380
374-383

(S)HMANEVI(K)
(I)KCKAAVA/(W)
(A)/AVAWEAGKPLSI(E)
(E)/IEVAPPKAHE/(V)
(E)/VRIKIIA/(T)
(E)/VRIKIIAT(A)
(A)/TAVCHTDAYTLSGAD(P)
(T)LSGAD(P)
(V)ILGHEGAGIVESVGEG(V)
(L)/GHEGAGIVESVGEGVT(K)
(E)/SVGEGVTKLKAGD(T)
(G)EGVTKLKAGD(T)
(I)PLYIPQCG(E)
(F)/TCKGKTIL/(H)
(L)/HYMGTST(F)
(T)AKLEPGSVC(A)
(L)/EPGSVCAVFGLGGV(G)
(S)VCAVFGLGGVGL/(A)
(M)GCKVAGASRII(G)
(G)CKVAGASRIIG(V)
(V)DINKDKFA/(R)
(D)KFARAKEFG(A)
(A)/RAKEFGATECIN(P)
(A)/KEFGATECINPQD(F)
(T)ECINPQD(F)
(D)FSKPIQEVL/(I)
(W)/KGTAFGGWKS(V)
(F)/GGWKSVESVPK(L)
(K)SVESVPKLVSE/(Y)
(S)EYMSKKIKVD(E)
(F)/DEINKAFE/(L)
(D)EINKAFELMH(S)
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72

73

74

75

76
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APPENDIX C – Supplementary Data for the development of pseudo-substrate 111
Table C1: 1H-NMR chemical shifts for the outlined reagents

Reagents
TFSNOG (500 MHz, D20, d)

Chemical Shifts (ppm)
2.06 (*m, 2H, Glu, Hb)
2.42 (t, 2H, Glu, Hg)
3.69 (b, 1H, Glu, Ha)
3.96 (s, 1H, Gly, Ha)
4.00 (b, 1H, Cys, Hb)
6.73-7.75 (aromatic H of fluoresceinyl protons)

TFHCys2 (500 MHz, D20, d)

2.29 (m, 1H, HCys, Ha)
2.73 (m, 2H, HCys, Hb)
3.58 (t, 2H, HCys, Hg)
6.32-7.57 (aromatic H of fluoresceinyl protons)

TFC2Cys2 (500 MHz, D20, d)

2.51 (t, 2H, Cys, Hb)
3.03 (q, 2H, Cys, Hb)
3.78 (t, 1H, Cys, Ha)
6.46-7.75 (aromatic H of fluoresceinyl protons)

*Abbreviations: δ, chemical shift in parts per million (ppm) downfield from the standard Multiplicities: s, singlet; t,
triplet; q, quartet; m, multiplet; b, broadened.
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Table C2: 1H-NMR chemical shift for GSNO and AOASNOG (OAbz-GSNO)
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Figure C1: TLC of starting materials and the products, after purification, visualized by UV lamp (254 nmplates A, B, C; 366 nm plate D) or I2 vapor. A- DTFCys2, B- DTFHCys2, C-TFSNOG, D-AOASNOG.
Multiple bands observed in FITC are due to prototropic forms of fluorescein (ref 13 in paper). The mobile
phase employed for DTFCys2, DTFHCys2, and TFSNOG was acetone: water: methanol in a 10:10:1. For
AOASNOG the mobile phase composition was acetone: water: methanol in a 13:6:1
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